Genetic aberrations in cancer cells can be of immediate relevance to t
he patient. They enable definitive diagnoses to be reached and sub-cla
ssification of certain tumour types into good or bad prognostic groups
, information which can influence therapy. These aberrations can also
be used as tumour markers for monitoring the response to therapy. Majo
r technological advances in the last few years have facilitated these
applications in the routine clinical setting and encouraged searches f
or new genetic markers. As the genes directly affected are identified
and their roles in tumorigenesis elucidated, they are likely to provid
e novel targets for therapeutic intervention.